Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial.
Hayes S, Obermair A, Mileshkin L, Davis A, Gordon LG, Eakin E, Janda M, Beesley VL, Barnes EH, Spence RR, Sandler C, Jones T, Vagenas D, Webb P, Andrews J, Brand A, Lee YC, Friedlander M, Pumpa K, O'Neille H, Williams M; ECHO Collaborative; Stockler M; ECHO trial. Hayes S, et al. Among authors: lee yc. BMJ Open. 2023 Apr 13;13(4):e067925. doi: 10.1136/bmjopen-2022-067925. BMJ Open. 2023. PMID: 37055210 Free PMC article. Clinical Trial.
Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.
Lee YC, Bressel M, Grant P, Russell P, Smith C, Picken S, Camm S, Kiely BE, Milne RL, McLachlan SA, Hickey M, Friedlander ML, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Lee YC, et al. Fam Cancer. 2017 Oct;16(4):461-469. doi: 10.1007/s10689-017-9977-x. Fam Cancer. 2017. PMID: 28285341 Free PMC article.
To Treat or Not to Treat.
Lee YC, Davis A. Lee YC, et al. JNCI Cancer Spectr. 2019 Apr 15;3(2):pkz023. doi: 10.1093/jncics/pkz023. eCollection 2019 Jun. JNCI Cancer Spectr. 2019. PMID: 31360900 Free PMC article. No abstract available.
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
Antill Y, Kok PS, Robledo K, Yip S, Cummins M, Smith D, Spurdle A, Barnes E, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Andrews J, Stockler MR, Mileshkin L; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Antill Y, et al. Among authors: lee yc. J Immunother Cancer. 2021 Jun;9(6):e002255. doi: 10.1136/jitc-2020-002255. J Immunother Cancer. 2021. PMID: 34103352 Free PMC article. Clinical Trial.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Cohen PA, Webb PM, King M, Obermair A, Gebski V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileshkin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Cohen PA, et al. Among authors: lee yc. Int J Gynecol Cancer. 2022 Apr 4;32(4):560-565. doi: 10.1136/ijgc-2021-002999. Int J Gynecol Cancer. 2022. PMID: 34551895 Clinical Trial.
Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M; HyNOVA Protocol Steering Committee. Farrell R, et al. Among authors: lee yc. J Gynecol Oncol. 2022 Jan;33(1):e1. doi: 10.3802/jgo.2022.33.e1. Epub 2021 Oct 18. J Gynecol Oncol. 2022. PMID: 34783204 Free PMC article.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Lee YC, et al. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. Int J Gynecol Cancer. 2022. PMID: 35086926 Free PMC article.
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study. Delahunty R, et al. Among authors: lee yc. J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9. J Clin Oncol. 2022. PMID: 35263119 Free PMC article.
5,497 results